Pfizer Inc. says it wants to actively engage in addressing the policy issue of affordable access, with the company looking to work with US president Joe Biden’s administration on finding “meaningful solutions” for patient access through incentivizing the uptake of biosimilars, as well as through rebate reform and capping beneficiary cost-sharing in Medicare Part D..
Albert Bourla, chairman and CEO of Pfizer commented, “We expect the Biden administration will soon announce a human capital component...







